LOS ANGELES--(BUSINESS WIRE)--In the current debate sparked by the recent USPSTF recommendation on PSA screening, it is clear that better biomarkers than PSA are urgently needed. One new biotechnology that may go a long way in detecting only prostate cancer and reducing unnecessary prostate cancer biopsies and possible subsequent overtreatment, is the development of a new urine test for prostate cancer. It was enabled by the discovery of specific prostate cancer DNA fusions in 2005 at the University of Michigan. This discovery opened the door to developing diagnostic tools that are specific only to prostate cancer.
